Joaquim Bellmunt B

This study identifies a tumor-cell MHC-II program linked to immunotherapy outcomes in bladder cancer across different stages and treatment settings.

This study identifies tumor-myeloid crosstalk as a driver of cisplatin resistance in bladder cancer and proposes PARP14 inhibition as a therapeutic strategy.

This study identifies epigenetic subtypes of high-grade T1 bladder cancer using integrated chromatin and transcriptomic data, revealing intra-tumor heterogeneity and distinct tumor microenvironment interactions.

APEX infers cancer gene expression from plasma cfChIP-seq data, outperforming existing methods and enabling subtype classification and biomarker identification.

The paper examines how platinum-based chemotherapy affects tumor immune microenvironments in urothelial cancer, finding that memory B cell infiltration correlates with improved survival in cisplatin-treated patients.

This study identifies factors predicting immunotherapy response in advanced bladder cancer using data from six cohorts.

The paper develops a machine learning model using transcriptomic data to predict chemotherapy response in muscle-invasive bladder cancer with high accuracy.